First-line selpercatinib for a patient with RET fusion-positive pulmonary large cell neuroendocrine carcinoma

First-line selpercatinib for a patient with RET fusion-positive pulmonary large cell neuroendocrine carcinoma

Pulmonary large cell neuroendocrine carcinoma (LCNEC) is an uncommon variant of non-small cell lung cancer (NSCLC), known for its aggressive behavior. This includes rapid progression, widespread metastases, and resistance to conventional chemotherapy, all of which contribute to a dismal prognosis. C...

Full description

Saved in:
Bibliographic Details
Main Authors: Tatsuru Eihuku, Seiichi Miwa, Tomoko Oshima, Hisano Ohba, Masahiro Shirai
Format: Article
Language:English
Published: Elsevier 2024-01-01
Series:Respiratory Medicine Case Reports
Subjects:
Large cell neuroendocrine carcinoma
Non-small cell lung cancer
RET rearrangements
Selpercatinib
Online Access:http://www.sciencedirect.com/science/article/pii/S2213007124001394
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://www.sciencedirect.com/science/article/pii/S2213007124001394

Similar Items